Bruker Launches NeofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications, TimsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
Portfolio Pulse from Benzinga Newsdesk
Bruker Corporation (NASDAQ: BRKR) has launched two new high-performance systems at the 72nd ASMS meeting: the neofleX MALDI-TOF/TOF system for mass spectrometry-based tissue imaging and the timsTOF Ultra 2 system for deep profiling of small cells and subcellular organelles. These innovations are expected to set new standards in 4D-Proteomics.
June 03, 2024 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bruker Corporation has launched the neofleX MALDI-TOF/TOF system and the timsTOF Ultra 2 system, which are expected to set new standards in 4D-Proteomics. This could enhance Bruker's market position and drive short-term stock price appreciation.
The launch of these advanced systems positions Bruker as a leader in the proteomics field, likely driving increased demand for their products and positively impacting their stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100